Trial Profile
A Study to Evaluate the Role of Vascular Density and Normalization in Response to Neoadjuvant Bevacizumab and Chemotherapy in Patients with Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- 08 Mar 2016 New trial record